{"id":"W2898272327","doi":"10.1093/annonc/mdy285.144","title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Endometrial cancer; Cohort; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Progressive disease; Oncology; Biomarker; Pharmacokinetics; Peripheral blood mononuclear cell; Clinical trial; Phases of clinical research; Cancer; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002062875,0.0008076002,0.0009059929,0.0003726469,0.0003005424,0.0007915575,0.0004799828,0.0004975743,0.001680263],"category_scores_gemma":[0.001386023,0.0003805078,0.0006550558,0.0003272918,0.0005404338,0.0005733111,0.0002903189,0.001456028,0.0003498032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007371686,"about_ca_system_score_gemma":0.0008464249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006122549,"about_ca_topic_score_gemma":0.001480507,"domain_scores_codex":[0.9994032,0.0003223203,0.00004253149,0.00006940391,0.00008001273,0.00008249586],"domain_scores_gemma":[0.9992132,0.0002006149,0.0001636317,0.0000853343,0.00005747045,0.0002796966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3213026,0.04130416,0.1051659,0.0008542004,0.001225327,0.001001051,0.001081462,0.005699897,0.2725045,0.0003605922,0.004759742,0.2447405],"study_design_scores_gemma":[0.04608907,0.7030795,0.1911053,0.00004244211,0.0008630462,0.001933252,0.0001632163,0.003567805,0.0454524,0.0002528148,0.007384349,0.00006686059],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973102,0.0008404398,0.0002927941,0.00009935061,0.000008720948,0.0002755103,0.0003996107,0.00002837766,0.0007450745],"genre_scores_gemma":[0.9962276,0.0003615956,0.0005767292,0.0002340901,0.00003773868,0.0002371126,0.001766022,0.00001432531,0.0005447048],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002062875,"threshold_uncertainty_score":0.01090962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05334834220999658,"score_gpt":0.4158929776229871,"score_spread":0.3625446354129905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}